Theravance Biopharma (NASDAQ:TBPH): Institutional Investor Sentiment Up to 1.78

December 20, 2017 - By Maria Brooks

 Theravance Biopharma (NASDAQ:TBPH): Institutional Investor Sentiment Up to 1.78

Sentiment for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) institutional sentiment increased to 1.78 in Q2 2017. Its up 0.54, from 1.24 in 2017Q1. The ratio increased, as 48 active investment managers increased or opened new holdings, while 27 cut down and sold their stock positions in Theravance Biopharma. The active investment managers in our partner’s database now possess: 34.25 million shares, up from 31.87 million shares in 2017Q1. Also, the number of active investment managers holding Theravance Biopharma in their top 10 holdings was flat from 4 to 4 for the same number . Sold All: 7 Reduced: 20 Increased: 33 New Position: 15.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.51 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

The stock decreased 3.00% or $0.86 during the last trading session, reaching $27.84. About 179,539 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has risen 89.85% since December 20, 2016 and is uptrending. It has outperformed by 73.15% the S&P500.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on February, 26. They expect $-1.15 EPS, up 15.44 % or $0.21 from last year’s $-1.36 per share. After $-1.27 actual EPS reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts -9.45 % EPS growth.

Cormorant Asset Management Llc holds 6.27% of its portfolio in Theravance Biopharma, Inc. for 950,000 shares. Foundation Asset Management Lp owns 451,306 shares or 5.99% of their US portfolio. Moreover, Baupost Group Llc Ma has 4.22% invested in the company for 9.27 million shares. The Massachusetts-based Opaleye Management Inc. has invested 3% in the stock. Old West Investment Management Llc, a California-based fund reported 120,777 shares.#img1#

Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $451,350 activity.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

Ratings analysis reveals 88% of Theravance Biopharma’s analysts are positive. Out of 8 Wall Street analysts rating Theravance Biopharma, 7 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. The lowest target is $14 while the high is $5500. The stock’s average target of $37.86 is 35.99% above today’s ($27.84) share price. TBPH was included in 19 notes of analysts from August 12, 2015. The firm earned “Buy” rating on Wednesday, November 8 by Needham. Robert W. Baird maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) on Monday, September 18 with “Sell” rating. Needham maintained the shares of TBPH in report on Wednesday, August 2 with “Buy” rating. The firm has “Buy” rating given on Tuesday, November 7 by Cantor Fitzgerald. Leerink Swann initiated it with “Outperform” rating and $26 target in Thursday, May 12 report. The company was initiated on Thursday, November 3 by Piper Jaffray. The rating was maintained by Cantor Fitzgerald on Wednesday, July 19 with “Buy”. The rating was maintained by Robert W. Baird with “Neutral” on Wednesday, August 12. The company was initiated on Monday, June 20 by Guggenheim. The firm earned “Sell” rating on Monday, October 30 by Robert W. Baird.

More news for Theravance Biopharma, Inc. (NASDAQ:TBPH) were recently published by: Seekingalpha.com, which released: “Theravance Biopharma: A High Risk-Reward Investment Opportunity” on December 18, 2017. Marketwatch.com‘s article titled: “Theravance Biopharma Inc.” and published on June 06, 2014 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: